Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.

Sung JK, Koh JH, Lee MY, Kim BH, Nam SM, Kim JH, Yoo JH, Kim SH, Hong SW, Lee EY, Choi R, Chung CH.

Yonsei Med J. 2010 May;51(3):385-91. doi: 10.3349/ymj.2010.51.3.385.

2.

Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo.

Hattori T, Matsubara A, Taniguchi K, Ogura Y.

Curr Eye Res. 2010 Feb;35(2):146-54. doi: 10.3109/02713680903447918.

PMID:
20136425
3.

Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats.

Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ.

Diabetes. 2003 Mar;52(3):864-71.

5.
6.
7.

Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase.

Liu WH, Hei ZQ, Nie H, Tang FT, Huang HQ, Li XJ, Deng YH, Chen SR, Guo FF, Huang WG, Chen FY, Liu PQ.

Chin Med J (Engl). 2008 Apr 20;121(8):706-12.

PMID:
18701023
8.

Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes.

Amano S, Yamagishi Si, Kato N, Inagaki Y, Okamoto T, Makino M, Taniko K, Hirooka H, Jomori T, Takeuchi M.

Biochem Biophys Res Commun. 2002 Nov 29;299(2):183-8.

PMID:
12437967
9.

Differential effects of selective endothelin type a receptor antagonist on the gene expression of vascular endothelial growth factor and its receptors in streptozotocin-induced diabetic heart.

Jesmin S, Zaedi S, Yamaguchi N, Maeda S, Shimojo N, Masuzawa K, Yamaguchi I, Goto K, Miyauchi T.

Exp Biol Med (Maywood). 2006 Jun;231(6):902-6.

PMID:
16741021
10.
11.

[Effects of losartan on the levels of angiotensin II and its type-1 receptor in diabetic rat kidney].

Wu W, Ding HL, Chen LH, Fu ZZ.

Nan Fang Yi Ke Da Xue Xue Bao. 2006 Dec;26(12):1742-4. Chinese.

12.

Effects of angiotensin receptor blocker on oxidative stress and cardio-renal function in streptozotocin-induced diabetic rats.

Arozal W, Watanabe K, Veeraveedu PT, Ma M, Thandavarayan RA, Suzuki K, Tachikawa H, Kodama M, Aizawa Y.

Biol Pharm Bull. 2009 Aug;32(8):1411-6.

13.

[The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].

Wang S, Li Y, Huang YJ.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011 Sep;27(9):1003-6. Chinese.

PMID:
21906476
14.

Effects of NADPH oxidase inhibitor on diabetic nephropathy in OLETF rats: the role of reducing oxidative stress in its protective property.

Nam SM, Lee MY, Koh JH, Park JH, Shin JY, Shin YG, Koh SB, Lee EY, Chung CH.

Diabetes Res Clin Pract. 2009 Feb;83(2):176-82. doi: 10.1016/j.diabres.2008.10.007. Epub 2008 Dec 25.

PMID:
19111363
15.

Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes.

Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, Gilbert RE.

Diabetes. 1999 Nov;48(11):2229-39.

PMID:
10535459
16.

Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.

Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H.

Diabetes. 2005 Oct;54(10):2891-903. Erratum in: Diabetes. 2006 Sep;55(9):2665.

17.

[Expression of VEGF in kidney of diabetic rats].

Chen ZJ, Yang YB, Huang SM.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jul;38(4):633-6. Chinese.

PMID:
17718428
18.

Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats.

Kohzuki M, Yasujima M, Kanazawa M, Yoshida K, Fu LP, Obara K, Saito T, Abe K.

J Hypertens. 1995 Jan;13(1):97-103.

PMID:
7759858
19.

Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats.

Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T.

J Diabetes Complications. 2003 Nov-Dec;17(6):374-9.

PMID:
14583184
20.

The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats.

Itagaki I, Shimizu K, Kamanaka Y, Ebata K, Kikkawa R, Haneda M, Shigeta Y.

Diabetes Res Clin Pract. 1994 Oct;25(3):147-54.

PMID:
7851268

Supplemental Content

Support Center